FMP
Kymera Therapeutics, Inc.
KYMR
NASDAQ
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
34.49 USD
0.12 (0.348%)
Balance Sheet
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Total Cash
21.34M
9.48M
7.07M
41.31M
177.98M
10.09M
11.58M
13.28M
15.23M
17.47M
Total Cash %
413.47
151.03
98.49
471.65
2.02k
99.7
99.7
99.7
99.7
Receivables
16.18M
438k
815k
1.74M
1.42M
3.12M
3.58M
4.11M
4.71M
5.41M
Receivables %
313.66
6.98
11.36
19.84
16.09
30.85
30.85
30.85
30.85
Inventories
2.52M
2.11M
2.2M
2.08M
1.69M
3.16M
3.62M
4.16M
4.77M
5.47M
Inventories %
48.86
33.67
30.61
23.73
19.1
31.19
31.19
31.19
31.19
Payable
2.18M
2.11M
3.76M
1.47M
815k
3.12M
3.58M
4.1M
4.71M
5.4M
Payable %
42.17
33.59
52.36
16.73
9.23
30.82
30.82
30.82
30.82
Cap Ex
-789k
-2M
-498k
-630k
-2.11M
-1.72M
-1.98M
-2.27M
-2.6M
-2.98M
Cap Ex %
-15.29
-31.84
-6.94
-7.19
-23.86
-17.02
-17.02
-17.02
-17.02
